Literature DB >> 9870209

Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease.

R Artuch1, M A Vilaseca, M Pineda.   

Abstract

Treatment strategies in mitochondrial diseases consist of several drugs that diminish the deleterious effects of the abnormal respiratory chain function, reduce the presence of toxic agents or correct deficiencies in essential cofactors. In this study we evaluated the monitoring of tocopherol, carnitine and ubiquinone concentrations in a group of paediatric patients during a follow-up period of 18 months and the response to treatment of these patients by means of the determination of blood lactate, plasma alanine and oxygen consumption by lymphocytes in relation to the clinical status of the patients. Tocopherol, carnitine and ubiquinone concentrations were easily corrected with therapy. Blood lactate proved the best biochemical tool to assess the response to treatment in paediatric patients. According to our results, improvement or stabilization of the clinical course seems to be more related to the biochemical or molecular defect than to the effectiveness of the treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870209     DOI: 10.1023/a:1005470702369

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  21 in total

1.  Automated analysis for free and short-chain acylcarnitine in plasma with a centrifugal analyzer.

Authors:  D S Roe; N Terada; D S Millington
Journal:  Clin Chem       Date:  1992-11       Impact factor: 8.327

Review 2.  Therapy of mitochondrial disorders.

Authors:  H Przyrembel
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

3.  Tocopherol in inborn errors of intermediary metabolism.

Authors:  D Moyano; M A Vilaseca; M Pineda; J Campistol; A Vernet; P Póo; R Artuch; C Sierra
Journal:  Clin Chim Acta       Date:  1997-07-25       Impact factor: 3.786

4.  Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease.

Authors:  P M Matthews; B Ford; R J Dandurand; D H Eidelman; D O'Connor; A Sherwin; G Karpati; F Andermann; D L Arnold
Journal:  Neurology       Date:  1993-05       Impact factor: 9.910

5.  Deficiency of subunits of Complex I and mitochondrial encephalomyopathy.

Authors:  T Ichiki; M Tanaka; M Nishikimi; H Suzuki; T Ozawa; M Kobayashi; Y Wada
Journal:  Ann Neurol       Date:  1988-03       Impact factor: 10.422

6.  Determination of lactate, pyruvate, beta-hydroxybutyrate and acetoacetate with a centrifugal analyser.

Authors:  R Artuch; M A Vilaseca; C Farré; F Ramon
Journal:  Eur J Clin Chem Clin Biochem       Date:  1995-08

Review 7.  Primary and secondary carnitine deficiency syndromes.

Authors:  R Pons; D C De Vivo
Journal:  J Child Neurol       Date:  1995-11       Impact factor: 1.987

8.  Successful treatment of pure myopathy, associated with complex I deficiency, with riboflavin and carnitine.

Authors:  P L Bernsen; F J Gabreëls; W Ruitenbeek; R C Sengers; A M Stadhouders; W O Renier
Journal:  Arch Neurol       Date:  1991-03

9.  Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy.

Authors:  Y Campos; R Huertas; G Lorenzo; J Bautista; E Gutiérrez; M Aparicio; L Alesso; J Arenas
Journal:  Muscle Nerve       Date:  1993-02       Impact factor: 3.217

10.  A mitochondrial myopathy with a defective respiratory chain and carnitine deficiency.

Authors:  R C Sengers; J C Fischer; J M Trijbels; W Ruitenbeek; A M Stadhouders; H J ter Laak; H H Jaspar
Journal:  Eur J Pediatr       Date:  1983-09       Impact factor: 3.183

View more
  8 in total

Review 1.  Nutritional Interventions for Mitochondrial OXPHOS Deficiencies: Mechanisms and Model Systems.

Authors:  Adam J Kuszak; Michael Graham Espey; Marni J Falk; Marissa A Holmbeck; Giovanni Manfredi; Gerald S Shadel; Hilary J Vernon; Zarazuela Zolkipli-Cunningham
Journal:  Annu Rev Pathol       Date:  2017-11-03       Impact factor: 23.472

2.  Mitochondrial Disease.

Authors:  Roser Pons; Darryl C. De Vivo
Journal:  Curr Treat Options Neurol       Date:  2001-05       Impact factor: 3.598

3.  Mitochondrial disease patients' perception of dietary supplements' use.

Authors:  Amel Karaa; Joshua Kriger; Johnston Grier; Amy Holbert; John L P Thompson; Sumit Parikh; Michio Hirano
Journal:  Mol Genet Metab       Date:  2016-07-16       Impact factor: 4.797

4.  Effect of high-dose vitamins, coenzyme Q and high-fat diet in paediatric patients with mitochondrial diseases.

Authors:  J Panetta; L J Smith; A Boneh
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 5.  Current and Emerging Clinical Treatment in Mitochondrial Disease.

Authors:  Rory J Tinker; Albert Z Lim; Renae J Stefanetti; Robert McFarland
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

6.  Nutrition Therapy for Mitochondrial Neurogastrointestinal Encephalopathy with Homozygous Mutation of the TYMP Gene.

Authors:  Jing Wang; Wei Chen; Fang Wang; Dong Wu; Jiaming Qian; Junren Kang; Hailong Li; Enling Ma
Journal:  Clin Nutr Res       Date:  2015-01-16

Review 7.  An Overview of Mitochondrial Protein Defects in Neuromuscular Diseases.

Authors:  Federica Marra; Paola Lunetti; Rosita Curcio; Francesco Massimo Lasorsa; Loredana Capobianco; Vito Porcelli; Vincenza Dolce; Giuseppe Fiermonte; Pasquale Scarcia
Journal:  Biomolecules       Date:  2021-11-04

Review 8.  Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.

Authors:  Sumit Parikh; Amy Goldstein; Mary Kay Koenig; Fernando Scaglia; Gregory M Enns; Russell Saneto; Irina Anselm; Bruce H Cohen; Marni J Falk; Carol Greene; Andrea L Gropman; Richard Haas; Michio Hirano; Phil Morgan; Katherine Sims; Mark Tarnopolsky; Johan L K Van Hove; Lynne Wolfe; Salvatore DiMauro
Journal:  Genet Med       Date:  2014-12-11       Impact factor: 8.822

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.